Eli Lilly’s Q2 2018 Earnings: New Products

New products portfolio

Eli Lilly & Co.’s (LLY) new products portfolio includes several drugs that have been launched since 2014. This portfolio includes Olumiant, Lartruvo, Taltz, Jardiance, Trulicity, Cyramza, Basaglar, and Verzenio. The chart below compares the revenues for LLY’s new products since the first quarter of 2017.

Eli Lilly’s Q2 2018 Earnings: New Products

Basaglar

Basaglar, an insulin glargine injection, reported 133.0% YoY (year-over-year) revenue growth to ~$201.8 million during the second quarter. Its revenues in the second quarter of 2017 totaled ~$86.6 million. This growth was driven by an increase in US sales to ~$156.5 million and nearly flat international sales of ~$45.3 million.

Jardiance

Jardiance, a part of the Boehringer Ingelheim and Eli Lilly’s diabetes alliance, reported revenues of ~$147.2 million during the second quarter. This represents 43.0% growth in YoY revenues compared to revenues of $103.2 million during the second quarter of 2017. The drug’s US sales increased 28.0%, and its international sales increased 70.0% in the quarter.

Taltz

Taltz reported revenues of $220.1 million during the second quarter, representing 59.0% growth in YoY revenues compared to $138.7 million during the second quarter of 2017. The drug’s US sales totaled $174.0 million, and its international sales totaled $46.0 million during the quarter.

Trulicity

Trulicity reported revenues of $779.8 million during the second quarter, representing 62.0% growth in YoY revenues compared to $480.2 million during the second quarter of 2017. The drug’s US sales increased ~61.0%, and its international sales rose ~69.0% during the quarter.

Verzenio

Verzenio is a new oncology drug for the treatment of HR+, HER2- advanced breast cancer, or metastatic breast cancer. Verzenio was launched in the US markets in the fourth quarter of 2017. Verzenio reported revenues of $57.7 million during the second quarter.

We discussed the performance of Cyramza and Lartruvo in Part 5 of this series.

The VanEck Vectors Pharmaceutical ETF (PPH) holds 4.8% of its total investments in Eli Lilly (LLY), 5.4% in Novartis AG (NVS), 5.4% in Sanofi (SNY), and 5.2% in Johnson & Johnson (JNJ).